Market Place
Sourcing Support
Curium Completes Early Enrollment of Phase 3 Prostate Cancer Trial
19 Nov 2024 //
GLOBENEWSWIRE
Curium ECLIPSE Trial Shows Statistically Significant Results
13 Nov 2024 //
GLOBENEWSWIRE
Curium Opens New Netherlands Facility for Lutetium-177
24 Sep 2024 //
GLOBENEWSWIRE
Curium`s PYLCLARI® Now Available In Spain
10 Sep 2024 //
GLOBENEWSWIRE
Curium Submits New Drug Application for Lutetium Lu 177 Dotatate Injection
09 Jul 2024 //
GLOBENEWSWIRE
Curium: Adds ILL Reactor For Lu-177 Supply Over 5 Years
05 Jun 2024 //
GLOBENEWSWIRE
Curium Launches Pylclari 18F-Psma PET Tracer For Prostate Cancer France
30 May 2024 //
GLOBENEWSWIRE
Curium Extends Lutetium-177 Supply Deal With NRG I PALLAS
29 May 2024 //
GLOBENEWSWIRE
Curium`s PYLCLARI® Approved In Germany For Prostate Cancer
06 May 2024 //
GLOBENEWSWIRE
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
22 Apr 2024 //
GLOBENEWSWIRE
Curium Announces Ioflupane I 123 Injection Availability for Friday Patient Use
06 Feb 2024 //
GLOBENEWSWIRE
Curasight A/S Achieves First Milestone under collaboration with Curium Inc.
22 Jan 2024 //
PR NEWSWIRE
Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
23 Nov 2023 //
GLOBENEWSWIRE
Curium Announces Achievement of Endpoints in Phase 2 Trial With Prostate Cancer
15 Aug 2023 //
GLOBENEWSWIRE
Curium Receives Marketing Authorization in the EU for PYLCLARI
28 Jul 2023 //
GLOBENEWSWIRE
Curium Announces Publication of DCFPyL Versus Fluoromethylcholine Results From European Phase III Study
21 Jul 2023 //
GLOBENEWSWIRE
Curium Receives Positive CHMP Opinion of PYLCLARI
26 May 2023 //
GLOBENEWSWIRE
Curium Announces Last Patient Enrolled in Phase 1/2 SOLAR Trial Imaging Men
23 May 2023 //
GLOBENEWSWIRE
Curium Confirms No Supply Challenges for its Eclipse Phase 3 Trial
14 Mar 2023 //
GLOBENEWSWIRE
Innovation and Growing Demand for Nuclear Medicine Drives Curium Expansion
02 Mar 2023 //
GLOBENEWSWIRE
Curium’s 14 Million Patients to Benefit From Regular Supply of Mo-99 and Tc-99
21 Dec 2022 //
GLOBENEWSWIRE
Curium Submits MAA for [18F]-DCFPyL to the EMA
27 Jun 2022 //
GLOBENEWSWIRE
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
03 May 2022 //
GLOBENEWSWIRE
Curium Announces Significant Increase in Detectnet Production Capacity
19 Apr 2022 //
GLOBENEWSWIRE
Curium Announces FDA Approval of Generic Version of DaTscan in the U.S.
05 Apr 2022 //
GLOBENEWSWIRE
Curium`s Generic Ioflupane Receives Approval in the U.S.
30 Mar 2022 //
FDA
Curium to become major player in the supply on non carrier added Lu-177
24 Jan 2022 //
GLOBENEWSWIRE
Curium Initiates ECLIPSE, a Ph3 Trial For Its Investigational Lu 177 PSMA I&T
27 Oct 2021 //
GLOBENEWSWIRE
Curium Announces Filing of a Generic Version of DaTscan in the U.S.
04 May 2021 //
GLOBENEWSWIRE
Coronavirus disruption scuppers Curium Pharma sale
18 Jun 2020 //
PM LIVE
Curium acquires Finnish Radiopharmaceuticals Company MAP Medical Technologies Oy
01 Dec 2019 //
GLOBE NEWSWIRE
